Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Hobeika, Liliane ^a   Self, Sally E ^b   Velez, Juan Carlos Q ^b  

^a University of Louisville School of Medicine   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Malignant hypertension; Proteasome inhibitor; Proteinuria; Thrombotic microangiopathy

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALBUMIN; BENAZEPRIL; BORTEZOMIB; CARFILZOMIB; CARVEDILOL; CITALOPRAM; CLONIDINE; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DILTIAZEM; EPLERENONE; ESOMEPRAZOLE; HEMOGLOBIN; HYDRALAZINE; IMMUNOGLOBULIN KAPPA CHAIN; LABETALOL; LENALIDOMIDE; MELPHALAN; METOPROLOL; NIFEDIPINE; THALIDOMIDE; TRAMADOL; VALSARTAN; ZOLPIDEM; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; OLIGOPEPTIDE; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; TENIPOSIDE;

ACUTE KIDNEY FAILURE; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ATROPHY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; COMPRESSION FRACTURE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE DURATION; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FIBROSING ALVEOLITIS; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYALINE DEGENERATION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; LEG EDEMA; MALE; MALIGNANT HYPERTENSION; MICROSCOPY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PODOCYTOPATHY; PROTEIN ELECTROPHORESIS; PROTEIN URINE LEVEL; PROTEINURIA; RELAPSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEPTIC SHOCK; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS; ACUTE KIDNEY INJURY; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; EDEMA; FATALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HYPERTENSION, RENAL; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PODOCYTE; RECURRENT DISEASE; SHOCK, SEPTIC;

ACUTE KIDNEY INJURY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE PROGRESSION; EDEMA; FATAL OUTCOME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERTENSION, RENAL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGOPEPTIDES; PODOCYTES; PROTEASOME INHIBITORS; PROTEINURIA; PYRAZINES; RECURRENCE; SHOCK, SEPTIC; TENIPOSIDE; THALIDOMIDE; THROMBOTIC MICROANGIOPATHIES;

EID: 84910648823     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-156     Document Type: Article

References (28)

1. Pathobiology of cast nephropathy from human Bence Jones proteins. Sanders PW, Booker BB, J Clin Invest 1992 89 2 630 doi:10.1172/JCI115629 10.1172/JCI115629 1737851
2. Hypercalcemia can potentiate the nephrotoxicity of Bence Jones proteins. Smolens P, Barnes JL, Kreisberg R, J Lab Clin Med 1987 110 460 465 3655525
3. Toxic acute tubular necrosis following treatment with zoledronate. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD, Kidney Int 2003 64 1 281 289 10.1046/j.1523-1755.2003.00071.x 12787420
4. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM, Leuk Lymphoma 2008 49 6 1108 1115 doi:10.1080/10428190802023707 10.1080/10428190802023707 18452093
5. Acute renal failure in hematopoietic cell transplantation. Parikh CR, Coca SG, Kidney Int 2006 69 3 430 435 10.1038/sj.ki.5000055 16395267
6. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Changsirikulchai S, Myerson D, Guthrie KA, McDonald GB, Alpers CE, Hingorani SR, Clin J Am Soc Nephrol 2009 4 2 345 353 doi:10.2215/CJN.02070508 10.2215/CJN.02070508 19144762
7. TTP-HUS associated with sunitinib. Choi MK, Hong JY, Jang JH, Lim HY, Cancer Res Treat 2008 40 4 211 213 doi:10.4143/crt.2008.40.4.211 10.4143/crt.2008.40.4.211 19688133
8. VEGF inhibition and renal thrombotic microangiopathy. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE, N Engl J Med 2008 358 11 1129 1136 doi:10.1056/NEJMoa0707330 10.1056/NEJMoa0707330 18337603
9. A method for estimating the probability of adverse drug reactions. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ, Clin Pharmacol Ther 1981 30 2 239 245 10.1038/clpt.1981.154 7249508
10. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Iacopino P, Pucci G, Arcese W, Bosi A, Falda M, Locatelli F, Marenco P, Miniero R, Morabito F, Rossetti F, Sica S, Uderzo C, Bacigalupo A, Bone Marrow Transplant 1999 24 1 47 51 10.1038/sj.bmt.1701830 10435734
11. Cyclosporin nephrotoxicity in heart and lung transplant patients. Griffiths MH, Crowe AV, Papadaki L, Banner NR, Yacoub MH, Thompson FD, Neild GH, Q J Med 1996 89 10 751 763 10.1093/qjmed/89.10.751
12. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Roy V, Rizvi MA, Vesely SK, George JN, Bone Marrow Transplant 2001 27 6 641 646 10.1038/sj.bmt.1702849 11319595
13. Fatal chronic relapsing thrombotic thrombocytopenic purpura following autologous bone marrow transplantation for chronic myeloid leukemia. Lugassy G, Ducach A, Blumenthal R, Bone Marrow Transplant 1998 21 8 859 860 10.1038/sj.bmt.1701171 9603418
14. Hemolytic uremic syndrome following autologous peripheral blood stem cell transplantation in a patient with malignant lymphoma. Ohno E, Ohtsuka E, Iwashita T, Uno N, Ogata M, Kikuchi H, Nasu M, Bone Marrow Transplant 1997 19 10 1045 1047 10.1038/sj.bmt.1700791 9169652
15. Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Morita R, Hashino S, Shirai S, Fujita N, Onozawa M, Kahata K, Kondo T, Imamura M, Asaka M, Int J Hematol 2008 88 2 248 250 doi:10.1007/s12185-008-0140-1 10.1007/s12185-008-0140-1 18636313
16. Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Moore H, Romeril K, Intern Med J 2011 41 4 348 350 doi:10.1111/j.1445-5994.2011.02458.x 10.1111/j.1445-5994.2011.02458.x 21507163
17. Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Salmenniemi U, Remes K, Hematol Rep 2012 4 2 13 doi:10.4081/hr.2012.e13 22826795
18. Bortezomib-induced thrombotic thrombocytopaenic purpura. Mehta N, Saxena A, Niesvizky R, BMJ Case Rep 2012 cr2012006461 doi:10.1136/bcr-2012-006461
19. NF-kappaB in cancer: from innocent bystander to major culprit. Karin M, Cao Y, Greten FR, Li ZW, Nat Rev Cancer 2002 2 4 301 310 10.1038/nrc780 12001991
20. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Usui J, Glezerman IG, Salvatore SP, Chandran CB, Flombaum CD, Seshan SV, Hum Pathol 2014 45 9 1918 1927 doi:10.1016/j.humpath.2014.05.015. Epub 2014 Jun 12 10.1016/j.humpath.2014.05.015 25087655
21. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study. Vigneau C, Lorcy N, Dolley-Hitze T, Jouan F, Arlot-Bonnemains Y, Laguerre B, Verhoest G, Goujon JM, Belaud-Rotureau MA, Rioux-Leclercq N, Nephrol Dial Transplant 2014 29 2 325 332 doi:10.1093/ndt/gft465. Epub 2013 Dec 2 10.1093/ndt/gft465 24302609
22. Bortezomib in multiple myeloma. Mateos MV, San Miguel JF, Best Pract Res Clin Haematol 2007 20 4 701 715 10.1016/j.beha.2007.09.003 18070714
23. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension: evidence for a maintenance role in quiescent adult endothelium. Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Chaudhry GM, Symes JF, Isner JM, Arterioscler Thromb Vasc Biol 1997 17 11 2793 2800 10.1161/01.ATV.17.11.2793 9409257
24. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD, Semin Nephrol 2010 30 6 591 601 doi:10.1016/j.semnephrol.2010.09.007 10.1016/j.semnephrol.2010.09.007 21146124
25. Use of bortezomib as anti-humoral therapy in kidney transplantation. Yang KS, Jeon H, Park Y, Jo IH, Kim JI, Moon IS, Choi BS, Park CW, Yang CW, Kim YS, Chung BH, J Korean Med Sci 2014 29 5 648 651 doi:10.3346/jkms.2014.29.5.648. Epub 2014 Apr 25 10.3346/jkms.2014.29.5.648 24851019
26. Bortezomib use in a pediatric cardiac transplant center. Zinn MD, L'Ecuyer TJ, Fagoaga OR, Aggarwal S, Pediatr Transplant 2014 18 5 469 476 doi:10.1111/petr.12300. Epub 2014 Jun 14. PMID: 24931171[PubMed-in process] 10.1111/petr.12300 24931171
27. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Eskandary F, Bond G, Schwaiger E, Kikic Z, Winzer C, Wahrmann M, Marinova L, Haslacher H, Regele H, Oberbauer R, Böhmig GA, Trials 2014 15 107 doi:10.1186/1745-6215-15-107 10.1186/1745-6215-15-107 24708575
28. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK, Cancer Res 2007 67 13 6383 6391 10.1158/0008-5472.CAN-06-4086 17616698